DGAP-News

Epigenomics AG: Journal of Molecular Diagnosis & Therapy publishes review of blood-based screening test Epi proColon(R) 2.0 CE

DGAP-News: Epigenomics AG / Key word(s): Study Epigenomics AG: Journal of Molecular Diagnosis & Therapy publishes review of blood-based screening test Epi proColon(R) 2.0 CE 14.02.2017 / 09:45 The issuer is solely responsible for the content of this announcement. Press release Journal of Molecular Diagnosis & Therapy publishes review of blood-based screening test Epi proColon(R) 2.0 CE

Liquid biopsy test delivers high sensitivity and specificity and may increase participation in cancer screening programs

Berlin (Germany) and Germantown, MD (U.S.A.), February 14, 2017 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), announced that an independent, peer-reviewed article on its blood-based colorectal cancer screening test Epi proColon 2.0 CE was published in the Journal of Molecular Diagnosis & Therapy.

According to the study authors Yvette N. Lamb and Sohita Dhillon, Epi proColon(R) 2.0 CE demonstrated high sensitivity and specificity in case control studies. Furthermore, it provides a patient-friendly option that may increase participation in colorectal cancer screening programs.

"This current comprehensive review adds to the increasing scientific evidence about the clinical performance of our liquid biopsy test Epi proColon", commented Greg Hamilton, Epigenomics' Chief Executive Officer. "We are convinced that a convenient, cost-effective blood test like Epi proColon holds significant promise for improving patient adherence to CRC screening, as patients readily accept this method of testing and blood tests could be easily incorporated into routine check-ups."

The article "Epi proColon(R) 2.0 CE: A Blood-Based Screening Test for Colorectal Cancer" can be accessed on the following website: http://link.springer.com/article/10.1007/s40291-017-0259-y

* Sensitivity: the percentage of cancer cases correctly identified; Specificity: the percentage of healthy individuals correctly identified as negative

About Epi proColon

For patients, the test only requires a blood sample drawn as part of routine healthcare provider visits. There are no dietary restrictions or alterations in medication required for the test. The sample will be analyzed at a national or regional diagnostic laboratory.